Logotype for JGC Holdings Corporation

JGC (1963) Q2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for JGC Holdings Corporation

Q2 2025 earnings summary

15 Jan, 2026

Executive summary

  • Net sales for FY2024/FY2025 were flat to up 0.9% year-on-year at ¥406.7 billion, with gross profit slightly down to ¥27.3–27.4 billion and a gross margin of 6.7%, impacted by yen appreciation.

  • Operating profit remained stable at ¥12.4 billion, while ordinary profit declined to ¥19.3–19.4 billion, mainly from foreign currency revaluation losses.

  • Profit attributable to owners was flat to up 1.5% at ¥12.7–12.8 billion, aided by a lower effective tax rate; EPS rose to ¥52.87.

  • Comprehensive income increased 6.6% year-over-year to ¥16.7 billion.

  • Consolidated orders in the first half reached approximately ¥370 billion, with a full-year target of ¥970 billion.

Financial highlights

  • Operating cash flow was strong at ¥58.3 billion, driven by project progress and receivables collection.

  • Investment and financing cash flows were both negative ¥14.7 billion, reflecting asset acquisitions, bond redemption, and dividend payments.

  • Cash and cash equivalents stood at ¥356.1 billion; total assets increased to ¥804.9 billion as of September 30, 2024.

  • Equity ratio remained stable or improved slightly at 48.9%.

  • Functional Materials Manufacturing net sales were ¥26–26.5 billion in the first half, with a full-year target of ¥52 billion.

Outlook and guidance

  • Full-year FY2025 net sales forecast at ¥830.0 billion, with operating profit projected at ¥26.0 billion and profit attributable to owners at ¥23.0 billion; annual dividend forecast maintained at ¥40 per share.

  • Full-year forecasts remain unchanged despite delays in project decisions and a 38% progress rate in new contracts.

  • Demand for natural gas and LNG is expected to remain strong, with clients advancing capital investments in transitional energy and sustainability.

  • Domestic investment plans in hydrogen, SAF, and biopharmaceuticals are progressing, though some are delayed due to subsidy timing and high costs.

  • Second half focus includes major LNG projects in Indonesia and Africa, and expansion in catalysts and fine chemicals.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more